PRRT2 and cardiac hypertrophy: Recent studies using transgenic mice with cardiac specific overexpression of PKC ε now suggest that low to moderate PKC ε activation, characterized by a 6 fold increase in translocation [7] or 228% increase in PKC activity [22] result in physiological cardiac hypertrophy with normal cardiac function.